Pharmacokinetics of indoramin in man.
作者信息
Draffan G H, Lewis P J, Firmin J L, Jordan T W, Dollery C T
出版信息
Br J Clin Pharmacol. 1976 Jun;3(3):489-95. doi: 10.1111/j.1365-2125.1976.tb00626.x.
Abstract
1 The fate of oral and intravenous indoramin has been studied after single doses in man using the 14C labelled drug. Plasma concentrations of indoramin have been determined during chronic oral antihypertensive therapy employing a stable isotope dilution assay. 2 Following singleoral dosing the drug is well absorbed and extensively metabolised. Faecal excretion in 72 h accounts for 46% of the administered radioactivity of which approximately 4% is associated with indoramin. Less than 2% of the radioactivity in urine is accountable as the concentration of total metabolites. Peak plasma levels both of drug and metabolites occur 1-2 h after dosing, the maximal lowering of blood pressure occurring at this time. 3 The clearance of indoramin, determined after intravenous administration is of the same order as liver blood flow. In the isolated perfused rat liver, the extraction ratio is 0.98.
摘要
相似文献
1
Pharmacokinetics of indoramin in man.
Br J Clin Pharmacol. 1976 Jun;3(3):489-95. doi: 10.1111/j.1365-2125.1976.tb00626.x.
2
Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.
Eur J Clin Pharmacol. 1983;25(2):243-6. doi: 10.1007/BF00543798.
3
Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.
Eur J Clin Pharmacol. 1983;24(5):629-34. doi: 10.1007/BF00542212.
4
Recent developments in the pharmacology and pharmacokinetics of indoramin.
J Cardiovasc Pharmacol. 1986;8 Suppl 2:S16-9. doi: 10.1097/00005344-198600082-00004.
5
Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
Eur J Clin Pharmacol. 1984;27(2):247-9. doi: 10.1007/BF00544054.
6
Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients.
J Cardiovasc Pharmacol. 1986;8 Suppl 2:S20-4. doi: 10.1097/00005344-198600082-00005.
7
A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.
Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634.
8
Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing.
Biopharm Drug Dispos. 1988 Mar-Apr;9(2):147-57. doi: 10.1002/bod.2510090204.
9
Pharmacokinetic interaction between indoramin and ethanol.
Hum Toxicol. 1989 May;8(3):237-41. doi: 10.1177/096032718900800306.
10
Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.
Drugs. 1986 Jun;31(6):467-99. doi: 10.2165/00003495-198631060-00002.
引用本文的文献
1
The authors reply.
Br Heart J. 1986 Feb;55(2):219-20. doi: 10.1136/hrt.55.2.219-b.
2
Clinical pharmacokinetics of vasodilators. Part II.
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
3
Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
Br J Clin Pharmacol. 1980 Sep;10(3):217-21. doi: 10.1111/j.1365-2125.1980.tb01747.x.
4
Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.
Eur J Clin Pharmacol. 1983;24(5):629-34. doi: 10.1007/BF00542212.
5
Death due to overdose of indoramin.
Br Med J (Clin Res Ed). 1982 Dec 4;285(6355):1660. doi: 10.1136/bmj.285.6355.1660-a.
6
Death due to overdose of indoramin.
Br Med J (Clin Res Ed). 1982 Oct 9;285(6347):1011. doi: 10.1136/bmj.285.6347.1011.
7
Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.
Eur J Clin Pharmacol. 1983;25(2):243-6. doi: 10.1007/BF00543798.
8
Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
Eur J Clin Pharmacol. 1984;27(2):247-9. doi: 10.1007/BF00544054.
9
Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.
Eur J Clin Pharmacol. 1987;32(6):619-23. doi: 10.1007/BF02455999.
10
Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.
Drugs. 1986 Jun;31(6):467-99. doi: 10.2165/00003495-198631060-00002.
本文引用的文献
1
Gluconeogenesis in the perfused rat liver.
Biochem J. 1966 Nov;101(2):284-92. doi: 10.1042/bj1010284.
2
Plasma propranolol levels in adults with observations in four children.
Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112-20. doi: 10.1002/cpt1970111112.
3
The dependence of paracetamol absorption on the rate of gastric emptying.
Br J Pharmacol. 1973 Feb;47(2):415-21. doi: 10.1111/j.1476-5381.1973.tb08339.x.
4
Pharmacologic studies of indoramin in man.
Clin Pharmacol Ther. 1972 May-Jun;13(3):380-92. doi: 10.1002/cpt1972133380.
5
Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.
N Engl J Med. 1972 Mar 23;286(12):617-22. doi: 10.1056/NEJM197203232861201.
6
Cardiovascular actions of Wy 21901, a new hypotensive and anti-arrhythmic agent.
Br J Pharmacol. 1970 Sep;40(1):151P-152P.
7
Clinical evaluation of indoramin, a new antihypertensive agent.
Eur J Clin Pharmacol. 1973 Dec;6(4):211-6. doi: 10.1007/BF00644733.
8
"First-pass" metabolism of paracetamol in rat liver.
J Pharm Pharmacol. 1974 May;26(5):348-51. doi: 10.1111/j.2042-7158.1974.tb09286.x.
Zotero 插件